Biomimetic quantum dot-labeled B16F10 murine melanoma cells as a tool to monitor early steps of lung metastasis by in vivo imaging by Díaz-García, V.M. et al.
© 2018 Díaz-García et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of Nanomedicine 2018:13 6391–6412
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
6391
O r I g I N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IJN.S165565
Biomimetic quantum dot-labeled B16F10 murine 
melanoma cells as a tool to monitor early steps 
of lung metastasis by in vivo imaging
Víctor Manuel Díaz-garcía,1–4 
simón guerrero,1,2,5 Natalia 
Díaz-Valdivia,1,2 lorena lobos-
gonzález,2,6,7 Marcelo Kogan,2,5 
José Manuel Pérez-Donoso,3 
andrew Fg Quest1,2
1cellular communication laboratory, 
center for studies on exercise, 
Metabolism and cancer (ceMc), Faculty of 
Medicine, Universidad de chile, santiago, 
chile; 2advanced center for chronic 
Diseases (accDis), Faculty of Medicine, 
Universidad de chile, santiago, chile; 
3BioNanotechnology and Microbiology 
laboratory, center for Bioinformatics 
and Integrative Biology (cBIB), Faculty of 
life sciences, Universidad andres Bello, 
santiago, chile; 4Facultad de Ingeniería y 
Tecnología, Universidad san sebastián, 
concepción 4080871, chile; 5Department 
of Pharmacological and Toxicological 
chemistry, Faculty of chemical and 
Pharmaceutical sciences, Universidad de 
chile, santiago, chile; 6Fundación ciencia y 
Vida, santiago, chile; 7centro de Medicina 
regenerativa, Facultad de Medicina, clínica 
alemana, Universidad del Desarrollo, 
santiago, chile
Background: Numerous studies have proposed the use of fluorescent semiconductor nanoparticles 
or quantum dots (QDs) as novel tools to label cells and tumors. However, QD applications are limited 
by their toxicity in biological systems and little is known about whether QDs affect the capacity of 
cancer cells to metastasize. Previously, we described the “biomimetic” synthesis of CdTe-QDs (QDs-
glutathione [GSH]) with increased biocompatibility and the potential utility in labeling cells.
Purpose: In order to determine the feasibility of using QDs-GSH as a tool for tracking tumor 
cells during early metastasis, we characterized here for the first time, the in vitro and in vivo 
effects of the incorporation of green or red biomimetic QDs-GSH into B16F10 cells, a syngeneic 
mouse melanoma line for metastasis assays in C57BL/6 mice.
Methods: B16F10 cells were labeled with green or red biomimetic QDs-GSH in the presence or 
absence of n-acetylcysteine. Then, migration, invasion and proliferation of labeled B16F10 were 
evaluated in vitro. Finally, the B16F10 cells labeled with red QDs-GSH were used to monitor in vivo 
lung metastasis at early time points (5 minutes to 24 hours)  or after 21 days in C57BL/6 mice.
Results: We developed a methodology that allows obtaining QDs-GSH-labeled B16F10 cells 
(nearly 100% viable labeled cells), which remained viable for at least 5 days and migrated 
similarly to control cells. However, proliferation, invasion, and the capacity to form metastatic 
nodules in the lungs were severely attenuated. Fluorescence imaging revealed that distribu-
tion/accumulation of QDs-GSH-labeled B16F10 cells could be tracked following injection 
into C57BL/6 mice (syngeneic preclinical metastasis model) and that these cells preferentially 
accumulated in the perialveolar area in lungs as early as 5 minutes post-injection.
Conclusion: The methodology described here represents a useful alternative for monitoring 
initial events during tumor cell metastasis.
Keywords: cell tracking, biomimetic, invasion, proliferation, migration, cancer
Introduction
Cancer is a leading cause of death world-wide1 and frequently attributable to tumor cell 
dissemination to distant organs, a process referred to as metastasis.2,3 The evolution 
of metastasis in vivo is difficult to follow, mainly because only a few tumor cells that 
enter the blood stream successfully colonize distant organs in a clinically detectable 
fashion.3 Standard in vivo experimental approaches to study metastasis involve the 
injection of metastatic cells into the blood stream of a mouse and subsequent evalu-
ation of distant organ invasion/colonization as metastatic foci after sacrificing the 
animal, generally several weeks post-inoculation of the tumor cells. Accordingly, these 
traditional methods are considered “black box” experiments, given that the events 
occurring between initial administration of cells and metastatic tumor formation in 
the target organ cannot be directly observed.4
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For in vivo imaging studies, fluorescence stands out over 
other techniques due to its low cost, high signal as well as 
spatial and temporal resolution, and the possibility of simulta-
neously evaluating multiple labels.4,5 The main disadvantages 
of fluorescence-based techniques include the instability of 
fluorescent probes and autofluorescence of biomolecules.4 
In the last decade, sensitivity, versatility and stability of 
fluorescence imaging applications have increased notably, 
thanks to the development of semiconductor nanoparticles 
(NPs) or quantum dots (QDs).4–6
QDs are inorganic, semiconducting, and fluorescent NPs, 
ranging in size from 1 to 20 nm approximately.7–9 The QD size 
determines their fluorescence emission wavelength, which 
may vary from 450 nm (blue-green) to 650 nm (red).7,8,10,11 
QDs possess a number of spectroscopic properties that make 
them particularly interesting for studies in vivo: 1) elevated 
resistance to chemical degradation and photobleaching; 
2) narrow and almost symmetric fluorescence peaks; 3) a 
broad light absorption spectrum that allows fine-tuning for 
processing of optical images and multispectral analysis of 
multiple objects simultaneously;7,10,11 and 4) a sensitivity 
that may be 2–3-fold higher than other organic fluorophores 
commonly used for detection in tissues.10,11 The aforemen-
tioned characteristics of QDs make them a promising tool 
for tumor and/or cell labeling, raising the specter of being 
able to track essentially real-time tumor cell migration, and 
their accumulation in distant organs.12
A major disadvantage of using QDs in biological systems is 
their toxicity associated with the formation of reactive oxygen 
species (ROS) and the release of heavy metal ions from the 
QDs core (ie, Cd+2 and Pb+2, among others).13–16 These ions 
interact with intracellular thiolated proteins and glutathione 
(GSH), thereby altering the cellular redox environment16–19 
and these changes likely affect the behavior of QDs-labeled 
metastatic cells.20 More recently, in an attempt to bypass 
these limitations, a new generation of cadmium-free QDs was 
developed, with essentially the same spectroscopic advan-
tages but lacking detrimental effects linked to the presence 
of cadmium. Nonetheless, some toxic effects attributable 
to physical and surface properties of these QDs remain.21
In this perspective, a few years ago, we developed a 
protocol to synthesize, in an ecofriendly and biocompat-
ible manner, cadmium-telluride QDs8 (Patent No US 
20130284979).22 This method, referred to as “Biomimetic,” 
permits obtaining rapidly and easily, hydrophilic QDs, 
stabilized with GSH on their surface (QDs-GSH), which 
emit fluorescence between 480 nm (green) and 650 nm 
(red), depending upon their size.8,9 QDs-GSH fluorescence 
was shown to remain stable for months when kept at room 
temperature. Moreover, QDs-GSH do not precipitate in 
buffers, cells, or bacterial culture media, in contrast to classic 
QDs.8 It is noteworthy that for QDs-GSH, no significant 
detrimental effects on human gastric cancer cell (MKN45) 
viability and morphology were detected after QDS-GSH 
internalization, even when incubated at concentrations 
up to 200 µg/mL.8,9,23 Nevertheless, it still remained to be 
determined how QDs-GSH affect migration, invasion, and 
metastasis of cancer cells.
In the current study, we extensively characterized the 
effects of QDs-GSH internalization on the viability, prolifera-
tion, and invasion in vitro, as well as lung metastasis in vivo 
of B16F10 murine melanoma cells in syngeneic C57BL/6 
mice, a preclinical melanoma model.24,25 QDs-GSH-labeled 
B16F10 cells were used to track the early accumulation/
distribution of these metastatic cells in C57BL/6 mice. 
Although QDs-GSH internalization severely reduced the 
ability of B16F10 cells to form visible metastatic nodules 
21 days post-injection, the QDs-GSH-labeled B16F10 cells 
could be successfully tracked during initial colonization of 
distant organs including the lung.
Materials and methods
QDs-gsh chemical synthesis
QDs-GSH were synthesized by protocols previously 
described by Pérez-Donoso et al.8,22 Citrate/NaBH
4
 15 mM 
(pH=9.4) solution was used as the synthesis buffer, to which 
CdCl
2
 40 µM, K
2
TeO
3
10 µM, and GSH 10 mM were added. 
The synthesis solution was incubated at 90°C shaking 
vigorously for 2 (green QDs-GSH [gQDs-GSH]) or 6 hours 
(red QDs-GSH [rQDs-GSH]) and the synthesis reaction 
was stopped by cooling to 4°C. QDs-GSH were dialyzed in 
Citrate/NaBH
4
 15 mM at pH 9.4, during 2 hours. Afterwards, 
QDs-GSH were precipitated using 2 volumes of ethanol for 
10 minutes at -20°C. Solutions were then centrifuged at 
24,000× g at 4°C for 20 minutes. Pellets were purified and 
vacuum dried for 24 hours at room temperature. Finally, QDs 
were weighed and dissolved in nanopure water.
QDs-gsh characterization
Solutions of different QDs-GSH (10 mg/mL) were charac-
terized by spectroscopy. Characterization was performed in 
96-well plates, using a multimodal multiplate reader (fluores-
cence and absorbance) (Sinergy-H1M; Biotek). Size and zeta 
potential were determined by dynamic light scattering and 
laser electrophoresis Doppler, respectively (Zetasizer nano 
S90 light; Malvern Instruments Limited, Malvern, UK). The 
core size of rQDs-GSH was determined by using a JEOL/JEM 
1200 EX II transmission electron microscope (Figure S1).
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cell culture and QDs-gsh incubation
B16F10 cells (provided originally by Dr Laurence Zitvogel, 
Institut Gustave Roussy, Villejuif, France) were cultured for 
24 hours in Roswell Park Memorial Institute medium (RPMI 
medium) (Gibco™; Thermo Fisher Scientific, Waltham, MA, 
USA) supplemented with 10% fetal bovine serum (FBS; 
Bioind) and antibiotics (penicillin 100 UI/mL, streptomycin 
100 µg/mL), at 37°C in 5% CO
2
. All procedures and the use 
of these cells were approved by the unit of risk prevention 
and biosafety, medical school, University of Chile and the 
institutional committee of care and use of animals (CICUA) 
of the University of Chile. Afterwards, QDs-GSH treatments 
were performed with the previously described culture medium 
supplemented with lipofectamine 4 µL/mL (Invitrogen), plus 
0, 50, 100, 200, or 400 µg/mL of each QDs-GSH. N-acetyl-
cysteine (NAC) treatments of 0, 2, 4, 8, or 10 mM were per-
formed using the same conditions, but only for rQDs-GSH.
Fluorescence-activated cell sorting (Facs)
Cell viability, labeled viable cells, mean fluorescence intensity 
(MFI) and ROS levels were determined by FACS flow cytom-
etry. B16F10 cells treated with red and green QDs-GSH were 
washed twice with PBS, detached with trypsin-EDTA 0.5%, 
and centrifuged at 150× g for 5 minutes. Then, cell pellets were 
washed with Flow Buffer (BD Biosciences, San José, CA, USA) 
and centrifuged as mentioned earlier. B16F10 cells treated with 
gQDs-GSH were incubated for 10 minutes with propidium 
iodide (PI) 10 µg/mL (Thermo Fisher Scientific) for death cell 
differentiation. On the other hand, B16F10 cells treated with 
rQDs-GSH were tested for green live cells-labeling (Calcein), 
with LIVE/DEAD® Viability/Cytotoxicity Kit, for mammalian 
cells (Thermo Fisher) dilution 1:100,000 to determine viability 
and with dihydrodichlorofluorescein (H2DCFDA) (Invitrogen) 
dilution 1:10,000 to determine ROS levels. Five thousand events 
were analyzed to determine size (forward scatter [FSC]) and 
granularity parameters (side scatter [SSC]), excluding cell debris. 
Cellular gQDs-GSH-fluorescence, cells
H2DCFDA
 and cells
Calcein
 were 
determined using the FITC channel (green fluorescence); rQDs-
GSH and PI mark were tracked in the PerCP-Cy5 channel (red 
fluorescence). Both emissions were obtained by laser excitation at 
488 nm. The percentage of viable labeled cells was obtained, for 
either red- or green-labeled cells, with the following equation:
 
% of viable labeled cells
Viable QDs GSH positible cells
To
= −
tal viable cells  
MFI was determined for viable QDs-labeled cells and 
control cells by FACs. Data were analyzed using the FCS 
Express four plus research edition software (De Novo Soft-
ware, Los Angeles, CA, USA).
confocal microscopy
Viable cells labeled or not with QDs-GSH were evaluated 
using a Zeiss Microscope model LSM 700. The excitation 
laser was set at 488 nm. Green and red fluorescence were 
tracked at 510 and 600 nm, respectively. All optical sections 
obtained for co-localization studies were processed with 
ImageJ 1.47 v software (National Institutes of Health, USA).
For invasion assays, fixed cells attached to the lower 
membrane surface were visualized using a Zeiss Microscope, 
model LSM 700. Wavelength excitation laser was set at 
405 nm. DAPI and rQDs-GSH fluorescence were tracked 
at 460 and 580 nm, respectively. Images of either B16F10 
or B16F10
QDs-GSH-10NAC
 cells attached to the lower side of 
the well membrane were obtained. Both types of cells were 
labeled with DAPI 1:1,000 for 5 minutes. Afterwards, mem-
branes were washed twice and fixed in DACO fluorescent 
solution.
Fluorescence microscopy
Membrane-attached cells after migration were visualized 
using a CKX41 inverted microscope and a fluorescence 
light source U-LH100HG (Olympus, Japan). Images were 
processed with ImageJ 1,47 v software (National Institutes 
of Health, USA).
Quantification of reduced thiols
B16F10 and MKN45 cells were cultured until they 
reached ~90% confluence in 100 mm plates. Afterwards, 
cells were collected, washed with PBS and resuspended 
in 200 µL sulfosalicylic acid 5% (SSA). Samples were 
divided into two equivalent portions, one for total protein 
measurement (BCA assay) and the other for the determina-
tion of intracellular thiols. Cells were lyzed using 20 freeze/
thaw cycles and subsequently centrifuged at 32,000× g for 
20 minutes. Supernatants were collected and reduced thiols 
(RSH) were quantified with Ellman’s reagent. Following 
incubation for 5 minutes at 37°C, the absorbance of super-
natants at 412 nm was determined.26,27 Calibration curves 
were obtained using GSH solutions of known concentra-
tion. Intracellular RSH levels were normalized to cellular 
protein content in milligrams.
Migration assays
Assays were performed using 8 µm pore polycarbonate mem-
brane transwells (diameter 6.5 mm) (Corning, NY, USA). After 
coating the lower membrane surface with 100 µL of fibronectin 
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2 µg/mL, membranes were washed with PBS. Afterwards, tran-
swells were immersed in RPMI medium supplemented with 
10% FBS. Suspensions of 1.5×105 cells (B16F10, B16F10
QDs-
GSH-4NAC
 or B16F10
QDs-GSH-10NAC
) prepared in serum-free RPMI 
medium were seeded into the upper chamber of transwells. 
After 2 hours, inserts were collected and the cells present in 
the upper chamber were removed. Cells attached to the lower 
membrane surface after migration were fixed and stained with 
a 0.1% crystal violet solution in methanol 20% for 2 hours at 
37°C. Membranes were then gently washed, dried at room 
temperature, mounted in Mowiol, and observed under a light 
microscope. At least seven fields were evaluated per experi-
ment to determine the number of transmigrated cells.
Invasion assays
Assays were performed using Matrigel Invasion Chambers 
(8 µm; Corning, NY, USA), which were rehydrated with RPMI 
media supplemented with 10% FBS. Subsequently, suspen-
sions of either B16F10 or B16F10
QDs-GSH-10NAC
 cells (2×105) 
prepared in serum-free RPMI medium were seeded into the 
upper transwell chamber. After 24 hours, inserts were collected 
and cells remaining in the upper chamber were removed. Cells 
that invaded the matrigel and then attached to the lower mem-
brane surface were fixed in cold methanol for 2 minutes and 
then stained with 1% Toluidine Blue for 2 hours. Membranes 
were then gently washed, dried at room temperature, mounted 
in Mowiol, and observed under a light microscope. At least 
seven fields were evaluated per experiment to determine the 
number of cells that invaded the matrigel.
rQDs-gsh cell labeling persistence and 
proliferation assay
This assay was performed using 1×105 viable cells 
(B16F10 cells and B16F10
QDs-GSH-10NAC
). Cells were seeded 
in 60 mm plates and cultured with RPMI-supplemented 
media. Afterwards, cells were detached with trypsin-EDTA 
0.5% and centrifuged at 150× g for 5 minutes. Cell pel-
lets were washed in PBS and centrifuged at 150× g for 
5 minutes; the supernatants were discarded and cells were 
resuspended in 200 µL of FBS. Then, the total number of 
cells 1–5 days post-inoculation was quantified in a Neu-
bauer chamber (Marienfeld Superior, Lauda-Königshofen, 
Germany) after trypan blue staining 0.5% (biological 
industries). Percentage of viability, labeled viable cells, 
and MFI were determined by FACS, as previously described.
In vivo metastasis assays
Experiments were done essentially following previously 
described protocols.25 Briefly, C57BL/6 mice were injected 
intravenously with 2×105 B16F10 or B16F10
QDs-GSH-10NAC
 
cells in 500 µL of physiological saline solution. Then, 
21 days post-injection, mice were sacrificed. Lungs were 
fixed in Fekete’s solution. Black lung tumor was separated 
from the rest of the lung tissue and weighed. Metastasis was 
expressed as black tissue mass/total lung mass percentage (%) 
post-fixation.
Mouse imaging
C57BL/6 mice were injected intravenously with 2×105 
B16F10 or B16F10
QDs-GSH-10NAC
 cells, in 500 µL of physiologi-
cal saline solution. Mice were observed for 6 hours using the 
in vivo imaging system (IVIS; In-Vivo FX PRO; Bruker, 
Billerica, MA, USA). Excitation and emission wavelengths 
were 410 and 600 nm, respectively. Afterwards, mice were 
euthanized and lungs were collected for ex-vivo imaging.
In vivo imaging
C57BL/6 mice were injected intravenously with 2×105 
B16F10
Control
 and B16F10
QDs-GSH-10NAC
 cells in 500 µL of 
physiological saline solution. Mice were sacrificed at 5 
minutes, 30 minutes, 2 hours, 6 hours, and 24 hours post-
injection. Lungs, heart, spleen, thymus, liver, and kidneys 
were harvested and fixed in Fekete’s solution for 1 week. 
Fluorescence present at the different time points was quan-
tified using IVIS, and are shown as the average of relative 
optical intensity (ROI). Fluorescence data are presented as 
percentages, considering the baseline fluorescence of unla-
beled organs as 100%.
Immunohistochemical analysis
The organs obtained from C57BL6 mice 6 and 24 hours after 
injection of B16F10
QDs-GSH-10NAC
, B16F10
Calcein
, or B16F10
Control
 
cells were fixed for 24 hours in pH7-buffered formalin (10%) 
and then paraffin-embedded. For tissue samples, 5 µm-thick 
serial paraffin sections were collected on silanized slides 
(DAKO) and deparaffinized in two consecutive 5-minute 
incubations with xylene. One section was then stained with 
hematoxylin and eosin (H&E). The others were rehydrated 
in two consecutive 3-minute incubations with 98% and 90% 
ethanol each, followed by a single incubation in Diethyl 
pyrocarbonate (DEPC)-treated distilled water for 5 minutes. 
Sections were then incubated in 2.5 µg/mL of Proteinase K 
(Invitrogen) at room temperature for 20 minutes and then 
rinsed twice for 3 minutes in DEPC-treated water. Nuclei were 
stained with DAPI for 5 minutes and washed. The samples 
were then mounted on cover slips and embedded with fluores-
cence mounting medium (DAKO). The images were captured 
using a fluorescence microscope (Olympus, Tokyo, Japan).
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Proof-of-concept
B16F10 cells stably transfected with either the empty 
pLacIOP vector [B16F10(Mock)] or the vector containing 
the Caveolin-1 (CAV1)-encoding insert [B16F10(CAV-1)] 
have been described previously.25,28 These cells were then 
labeled with rQDs-GSH as described earlier (B16F10
QDs-
GSH-10NAC
). C57BL/6 mice were injected intravenously with 
2×105 of the respective cells in 500 µL of physiological 
saline solution. Mice were sacrificed 6 hours post-injection 
of cells and lungs were fixed in Fekete’s solution for 1 week. 
Then, fluorescence was quantified (average ROI) using the 
IVIS system.
statistical analysis
Data shown are the average±SEM of at least three indepen-
dent experiments. Statistical significance was determined at 
a 95% CI using the nonparametric Mann–Whitney test, for 
the comparison of two groups.
All in vivo assays were performed as blind studies (in vivo 
metastasis assays and in vivo images) or double-blind studies 
(mice and lung images, immunohistochemistry assay, and 
proof-of-concept). All in vivo experiments were performed 
following the protocols of management and care of animals 
established by the CICUA of the University of Chile. CICUA 
approval code: CBA # 0837 FMUCH.
Results and discussion
synthesis and characterization of 
QDs-gsh
In this study, green and red QDs-GSH were synthesized using 
the biomimetic method developed by our laboratory.8,9,22 
Data summarizing the size distribution, zeta potential, and 
emission peak wavelengths of QDs-GSH are shown in 
Table 1. For gQDs-GSH, zeta potential values were greater 
than those of rQDs-GSH. GSH is a tripeptide, with a thiol 
and two carboxyl-terminal groups, which confer negative 
charges to the molecule.17 Thus, the elevated zeta potential 
is indicative of a higher GSH content in the gQDs-GSH. We 
previously characterized by X-ray photoelectron spectros-
copy (XPS) the GSH-QD capping and reported a lower GSH 
content in rQDs-GSH than gQDs-GSH.23 Importantly, dif-
ferences in QDs size (gQDs-GSH vs rQDs-GSH) and charge 
have previously been shown to affect cell viability.7,9,15,21,29 In 
addition, we have previously reported that green biomimetic 
QDs-GSH contain less Cd2+ than rQDs-GSH (18% and 30%, 
respectively).8,9 Therefore, in vitro assays were performed 
to evaluate cell behavior after incorporation of gQDs-GSH 
and rQDs-GSH.
characterization of QDs-gsh 
internalization and effects in B16F10 cells
B16F10 murine melanomas are cancer cells with an 
elevated metastatic potential that specifically accumulate 
in the lungs following tail vein injection of syngeneic 
C57BL/6 recipient animals, where they form readily 
detectable, pigmented metastatic nodules 15–21 days 
post-injection.24,25 This is a well-established preclinical 
model that is employed to evaluate the metastatic potential 
of cancer cells.24,25 To label the B16F10 cells, they were 
incubated with gQDs-GSH or rQDs-GSH at concentrations 
ranging from 0 (control) to 50, 100, 200, or 400 µg/mL, in 
the presence of 4 µL/mL of lipofectamine, for 24 hours. 
Lipofectamine was used to promote cell internalization 
of QDs-GSH, following a previously described proto-
col8 (Patent No US 20130284979).22 Then, cell viability, 
percentage of viable labeled cells, and the MFI of cells 
transfected with different concentrations of QDs-GSH 
were determined by flow cytometry (Figure 1A). For 
gQDs-GSH, cell viability in general and viability of labeled 
cells were substantially reduced at concentrations of 50 
µg/mL or higher (Figure 1B). In this respect, rQDs-GSH 
were significantly less toxic and also the MFI for labeled 
cells was higher in comparison to those obtained with 
gQDs-GSH (Figure 1C and D). Note that rQDs-GSH only 
induced significant decreases in cell viability when used 
at higher concentrations (400 µg/mL). These observations 
are consistent with reports by Lovrić et al,30 who showed 
that smaller sized QDs more readily crossed intracellular 
membranes to enter the nucleus and other subcellular com-
partments, like mitochondria.8,31 The nuclear pore complex 
permits entry of small molecules up to ~9 nm in diameter by 
passive diffusion.32 Our results show that gQDs-GSH and 
rQDs-GSH possess a hydrodynamic diameter of ~1.8 and 
~5.1 nm (Table 1), respectively, indicating that both QDs-
GSH probably can cross the nuclear membrane, although 
gQDs-GSH are likely do so more efficiently. However, QDs 
toxicity may also relate to the differences in zeta potential 
Table 1 size (hydrodynamic diameter), Z potential, and emission 
peaks of green and rQDs-gsh
gQDs-GSH rQDs-GSH
size (nm) 1.8±0.2 5.1±1.1
Z potential (mV) -43.5±0.8 -13.6±2.2
emission peak (nm) 490 610
Abbreviations: gsh, glutathione; gQDs-gsh, green QDs-gsh; QDs, quantum 
dots; rQDs-gsh, red QDs-gsh.
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between gQDs-GSH and rQDs-GSH, given that greater 
negative zeta potential values, as is the case for gQDs-GSH, 
are known to reduce cell survival31 (Table 1).
Of note, the detrimental effects observed in B16F10 cells 
incubated with gQDs-GSH were significantly elevated in 
comparison to the toxic effects of biomimetic QDs previously 
reported for MKN45 cells.8,9,23 This may simply reflect cell-
specific parameters of predisposition to QDs-GSH toxicity, as 
has been reported previously in different cell lines exposed to 
inorganic NPs.33 Alternatively, it is well established that the 
generation of ROS represents one of the main mechanisms 
by which QDs induce damage to biological systems.13–15,19 
Intracellular thiols (RSH) play an important role as mediators 
of tolerance to intracellular ROS.17,18 Thus, we hypothesized 
that the differences in sensitivity to QDs-GSH observed for 
B16F10 and MKN45 cells may be due to different levels of 
RSH. To evaluate this possibility, intracellular RSH levels 
were determined in each cell type. As suspected, significantly 
lower RSH levels were observed in B16F10 cells than in 
MKN45 cells, suggesting that B16F10 cells may, for this 
reason, tolerate to a lesser extent QD-induced oxidative 
damage than MKN45 cells (Figure S2).
Nac treatment reduces rQDs-gsh 
effects in B16F10 cells and increases cell 
labeling
QDs increase ROS in biological systems,14 and ROS, on the 
other hand, affects migration and invasion of metastatic cells.34 
Therefore, we hypothesized that NAC should ameliorate 
detrimental QDs-GSH effects on metastatic cells, given that 
NAC increases intracellular RSH levels.17 Moreover, NAC is 
generally beneficial and protects cells against organic stress 
induced by inorganic NPs,33 as well as provides greater protec-
tion against QDs damage than other non-thiol anti-oxidants, 
such as trolox.30 Given our results showing that incubation of 
cells with 100 µg/mL of rQDs-GSH resulted in .80% viable 
labeled cells, similar to the percentage of viable labeled cells 
reported by Voura et al,12 with the best mean MFI values 
(Figure 1C and D), as well as the fact that fluorescence emis-
sion at longer wavelengths is absorbed to a lesser extent by 
tissues,4 we focused on characterizing the behavior of B16F10 
cells after labeling with 100 µg/mL rQDs-GSH.
To assess the benefits of NAC, B16F10 cells were 
cultured as previously mentioned, but this time different 
concentrations of NAC were added in both culture steps 
(Figure 2A). Afterwards, cell viability, ROS levels, viable 
Figure 1 B16F10 cells viability after rQDs-gsh and gQDs-gsh incorporation.
Notes: (A) Dot plot of B16F10 cells labeled with gQDs-gsh or rQDs-gsh (100 µg/ml), and B16F10 control cells. events were gated to show B16F10 gQDs-gsh+ or 
rQDs-gsh+ cells and live or dead B16F10 cells. (B) effects on B16F10 cell viability of treatments with lipofectamine and gQDs-gsh or rQDs-gsh. (C) comparison of viable 
labeled cells treated with either rQDs-gsh or gQDs-gsh, and lipofectamine. (D) comparison of MFI associated with either rQDs-gsh or gQDs-gsh in viable B16F10 cells. 
results were averaged from 3 to 4 independent experiments (n=3–4). Data were analyzed using the nonparametric Mann–Whitney test. Statistically significant differences 
compared with the controls and different treatments are indicated.
Abbreviations: GSH, glutathione; gQDs-GSH, green QDs-GSH; MFI, mean fluorescence intensity; QDs, quantum dots; rQDs-GSH, red QDs-GSH.
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labeled cells, and MFI associated with QDs-GSH presence 
in viable cells were detected by flow cytometry (Figure 2B). 
rQDs-GSH were incorporated by B16F10 cells and intracel-
lular distribution was similar (Figure 2C) to that described 
in previous studies.8,9,23 ROS levels were lower when cells 
were co-incubated with rQDs-GSH in the presence of NAC 
(Figure 2D). Nearly 100% viable labeled B16F10 cells were 
obtained when incubated with 10 mM NAC (Figure 2E). 
Also, a general increase in MFI values after exposure to 8 and 
10 mM NAC was observed (Figure 2F). Because fluorescence 
is proportional to the QDs-GSH concentration,8 this suggests 
that addition of NAC to cell cultures promotes QDs-GSH 
internalization, possibly by reducing ROS formation upon 
QDs uptake.30 Finally, NAC treatments allowed obtaining 
nearly 100% viable labeled cells with increased fluorescence 
signal and ROS levels similar to unlabeled cells.
effects of rQDs-gsh and Nac 
treatment on functional parameters 
of B16F10 cells
To compare NAC effects, cells were incubated with 100 µg/mL 
of rQDs-GSH in the presence of either 4 (maximum NAC 
concentration that did not significantly increase the MFI) 
or 10 mM NAC (upper limit NAC concentration used for 
Figure 2 effects of Nac treatment on rOs levels, viability, and incorporation of rQDs-gsh into B16F10 cells.
Notes: (A) schematic summarizing the labeling assays in the presence of Nac. (B) Dot plot of B16F10 cells labeled with h2DcFDa or rQDs-gsh (100 µg/ml) and B16F10 
control cells. events were gated to show B16F10 h2DcFDa+ or rQDs-gsh+ B16F10 cells. (C) confocal imaging of viable B16F10 cells (calcein labeled) with or without 
rQDs-gsh. (D) rOs levels of B16F10 cells labeled with 100 µg/ml of rQDs-gsh in the presence of 0, 4, or 10 mM Nac during the labeling process. (E) Percentage of 
viable rQDs-gsh-labeled B16F10 cells in the presence of different Nac concentrations. (F) MFI associated with QDs-GSH fluorescence in viable rQDs-GSH-labeled B16F10 
cells in the presence of different Nac concentrations. results were averaged from 3 to 6 independent experiments (n=3–6). Data were analyzed using the nonparametric 
Mann–Whitney test. Statistically significant differences compared with the controls and different treatments are indicated.
Abbreviations: GSH, glutathione; H2DCFDA, dichlorodihydrofluorescein; hrs, hours; MFI, mean fluorescence intensity; NAC, N-acetylcysteine; QDs, quantum dots; 
rQDs-gsh, red QDs-gsh.
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Figure 3 Migration and invasion of B16F10 cells labeled with rQDs-gsh in the presence of Nac.
Notes: (A) Images obtained by epifluorescence optical microscopy of migratory B16F10 control, B16F10QDs-gsh-4Nac, and B16F10QDs-gsh-4Nac cells. In circles, migratory cells; 
white arrows: fluorescent cells; black arrows: migratory rQDs-GSH-labeled cells. (B) Quantification of the migration of B16F10QDs-gsh-4Nac, B16F10QDs-gsh-10Nac, and control 
cells. (C) Images obtained by epifluorescence optical microscopy of invading B16F10 control, B16F10QDs-gsh-4Nac, and B16F10QDs-gsh-4Nac cells. In circles, migratory cells; white 
arrows: fluorescent cells; black arrows: migratory rQDs-GSH-labeled cells. (D) confocal microscopy of invading B16F10QDs-gsh-4Nac and B16F10 cells. (E) Quantification of 
the invasiveness of B16F10QDs-gsh-4Nac, B16F10QDs-gsh-10Nac, and control cells. results were averaged from three independent experiments (n=3). Data were analyzed using the 
nonparametric Mann–Whitney test. Statistically significant differences compared with the controls and different treatments are indicated.
Abbreviations: B16F10QDs-gsh-4Nac, B16F10 cells labeled with rQDs-gshin presence of 4 mM of Nac; B16F10QDs-gsh-10Nac, B16F10 cells labeled with rQDs-gsh in presence 
of 10 mM of Nac; gsh, glutathione; Nac, N-acetylcysteine; QDs, quantum dots; rQDs-gsh, red QDs-gsh.
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treatment) to generate B16F10
QDs-GSH-4NAC
 and B16F10
QDs-
GSH-10NAC
, respectively. Subsequently, cells were evaluated in 
vitro in migration and invasion assays.
Migration was 2.8 times higher for B16F10
QDs-GSH-4NAC
 than 
control cells (Figure 3A and B). On the other hand, no differ-
ences in migration were observed when B16F10
QDs-GSH-10NAC
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cells were compared with control cells. This suggests that 
B16F10 cells with internalized rQDs-GSH increase migra-
tion at lower NAC concentrations, likely as the consequence 
of increased intracellular ROS levels (Figure 2D) that are 
known to promote cancer cell migration.34 Therefore, NAC 
pretreatment permitted ameliorating undesirable effects 
observed following QDs-GSH internalization related to intra-
cellular ROS levels, and allowed obtaining QDs-GSH-labeled 
B16F10 cells that migrated like the unlabeled cells.
Likewise, rQDs-GSH-labeled B16F10 cells were still able 
to invade in a matrigel invasion assay (Figure 3C), maintaining 
the labeling associated with QDs-GSHr (Figure 3C and D), but 
did so much less effectively. rQDs-GSH presence significantly 
decreased invasion for both B16F10
QDs-GSH-4NAC
 and B16F10QD-
s
QDs-GSH-10NAC
, to 41% and 6%, respectively (Figure 3E). These 
results suggest that greater amounts of internalized rQDs-GSH 
(Figure 2F) correlate with a reduction in cell invasiveness. 
Thus, because augmenting intracellular ROS levels increases 
cell metastasis,34 our results indicate that internalization of 
rQDs-GSH in B16F10 cells decreases invasiveness in a ROS-
independent fashion. A possible explanation might be that Cd2+ 
in rQDS-GSH reduces the activity of matrix metalloproteinases 
(MMPs), which are zinc-containing endopeptidases capable of 
degrading extracellular matrix (ECM) proteins.35 MMPs are 
exocytosed by metastatic cells and mediate tumor microenviron-
ment changes during cancer progression, favoring metastatic cell 
invasion.36 B16F10 exposure to Cd+2 has been shown to reduce 
cell invasiveness due to upregulation of tissue inhibitor of metal-
loproteinase-1 (TIMP-1) expression, which is Cd+2-dependent.37 
In addition, our results show that the methodology employed 
here permits obtaining rQDs-GSH-labeled B16F10 cells that 
migrate similarly to unlabeled cells, but display dramatically 
reduced invasiveness. These results suggest that the invasiveness 
of rQDs-GSH-labeled cells is reduced by a cadmium-dependent 
mechanism, but further experimentation beyond the scope of 
this study is required to confirm this possibility.
Therefore, rQDs-GSH-labeled cells can be useful for 
in vivo studies of metastasis steps where migration is relevant 
(ie, distribution of metastatic cells throughout the body and 
transendothelial migration). With this in mind, we envisioned 
that B16F10
QDS-GSH-10NAC
 cells might be useful to monitor early 
steps in metastasis. To this end, viability, proliferation, and 
QD-clearance were evaluated for 5 days after labeling using 
B16F10
QDS-GSH-10NAC
 cells.
Proliferation of B16F10QDs-gsh-10Nac and 
persistence of labeling
Intracellular NP content may be reduced by different mecha-
nisms, such as cell death, cell proliferation, NP diffusion, 
lysosomal degradation, and/or transcytosis and exocytosis.38 
For example, D-penicillamine-coated QDs (DPA-QDs) 
were not degraded in the lysosomal compartment during 
the first 24 hours post-internalization,39 but rather were 
rapidly exocytosed (half-life of 21 minutes). Therefore, it 
was important here to determine rQD-GSH persistence in 
B16F10 cells prior to the subsequent evaluation in in vivo 
metastasis assays. B16F10
QDs-GSH-10NAC
 cells were cultured in 
RPMI supplemented with 10% BFS for 5 days and the total 
cell number (quantification of proliferation), cell viability, 
percentage of viable labeled cells, and MFI were determined 
after cell labeling (Figure 4). B16F10
QDs-GSH-10NAC
 viability 
was not substantially reduced during a 5-day period post-
labeling (Figure 4A), although a slight decline in viability 
was observed after the third day (to 79%), which then 
remained stable up to day 5. A significant reduction in 
MFI was observed from the second day onwards, which 
resulted in a reduction of the fluorescence intensity by 43% 
after 5 days (Figure 4C). The data obtained suggest that 
B16F10
QDs-GSH-10NAC
 cells remain viable with a stable percent-
age of viable labeled cells for at least 3 days (Figure 4B), and 
that the MFI does not vary significantly until the second-day 
post-labeling. Thus, the labeling methodology described here 
employing biomimetic QDs-GSH allows for more prolonged 
cell labeling than other QDs-based methodologies described 
in the literature (on the order of minutes).39 Interestingly, 
B16F10
QDs-GSH-10NAC
 cells appear unable to proliferate, since 
no increase in the total number of cells was observed during 
the 5 days of the assay (Figure 4D). For rQDs-GSH-labeled 
B16F10 cells, in the absence of NAC treatments (lower case 
labeling in Figure 2), the total number of cells was found 
to increase 24 hours post-labeling in a manner similar to 
unlabeled cells (Figure S3D), whereby viability, percentage 
of labeled cells, and MFI were maintained (Figure S3A–C). 
These results are in agreement with previous publications 
indicating that NP internalization may affect cellular prolif-
eration40 and that Cd2+ inhibits cell proliferation in a dose-
dependent manner.41,42 Thus, the methodology described here 
has the potential to be used as a cell-labeling strategy to study 
early steps in vivo involved in accumulation/distribution of 
metastatic cells in distant organs.
In vivo metastasis assays
For the in vivo studies, we employed a syngeneic metasta-
sis model in C57BL/6 mice with an intact immune system. 
B16F10
QDs-GSH-10NAC
 cells were injected into the tail vein of 
mice and 21 days post-injection mouse survival and tumor 
mass in the lungs were determined (Figure 5A). Administra-
tion of B16F10
QDs-GSH-10NAC
 cells did not alter mouse survival 
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Figure 4 effects of QDs-gsh labeling on B16F10 cell proliferation and QDs-gsh signal persistence.
Notes: (A) B16F10QDs-gsh-10Nac and control cell viability. (B) Percentage of viable B16F10QDs-gsh-10Nac cells. (C) MFI of viable B16F10QDs-gsh-10Nac cells. (D) Total number of 
B16F10QDs-gsh-10Nac cells. results were obtained over a 5-day period after labeling and averaged from 3 to 6 independent experiments (n=3–6). Data were analyzed using the 
nonparametric Mann–Whitney test. Statistically significant differences compared with the controls and different treatments are indicated.
Abbreviations: B16F10QDs-gsh-10Nac, B16F10 cells labeled with rQDs-GSH in presence of 10 mM of NAC; GSH, glutathione; MFI, mean fluorescence intensity; NAC, 
N-acetylcysteine; QDs, quantum dots; rQDs-gsh, red QDs-gsh.
Figure 5 In vivo metastasis assays using rQDs-gsh-labeled B16F10 cells.
Notes: B16F10QDs-gsh-10Nac and control cells were injected into the tail vein of C57BL/6 mice. After 21 days, mice were sacrificed and lungs were collected. (A) scheme 
summarizing the time course of metastasis assays. (B) c57Bl/6 mouse survival up to 21 days post-injection of B16F10 (dashed line) or B16F10QDs-gsh-10Nac (solid line) cells. 
(C) Determination of tumor mass present in lungs from c57Bl/6 mice at 21 days post-injection of B16F10 control or B16F10QDs-gsh-10Nac cells. results were averaged from 
8 (B16F10 control cells) or 12 (B16F10QDs-gsh-10Nac cells) independent experiments in mice (n=8–12). Data were analyzed using the nonparametric Mann–Whitney test. 
Statistically significant differences compared with the controls and different treatments are indicated. Note that the data shown were obtained in a double-blind study.
Abbreviations: B16F10QDs-gsh-10Nac, B16F10 cells labeled with rQDs-gsh in presence of 10 mM of Nac; gsh, glutathione; Nac, N-acetylcysteine; QDs, quantum dots; 
rQDs-gsh, red QDs-gsh.
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(Figure 5B). After necropsy, metastasis remained undetect-
able in over 90% of the B16F10
QDs-GSH-10NAC
 treated mice; 
lung tumor mass in the only mouse with metastasis was 
equivalent to only 1.4% of total lung mass. To the contrary, 
metastatic lung nodules were detected in all control mice 
injected with the same number of B16F10 cells (Figure 5C) 
and accounted for 14.5% of lung mass, similar to what we 
have described in our previous publications.25,28 These results 
show that incorporating QDs into B16F10 cells, as is the case 
for B16F10
QDs-GSH-10NAC
, significantly reduces the ability of 
these cells to form metastatic nodules in vivo 21 days post-
injection. This is in agreement with the in vitro data showing 
that labeled cells neither invade nor proliferate (Figures 3E 
and 4D). On the other hand, the use of B16F10 cells labeled 
with CdSe/ZnS QDs capped with dihydrolipoic acid (DHLA) 
was reported using lipofectamine-aided transfection for inter-
nalization of QDs-DHLA. However, in those experiments, 
the authors observed that B16F10 cells formed metastatic 
nodules 40 days post-injection.12 These differences may be 
attributable to variations in the amount of QDs-GSH present 
and Cd2+ release inside B16F10
QDs-GSH-10NAC
 cells. Thus, using 
our methodology, QDs-GSH-labeled cells were obtained 
that migrated similarly to unlabeled cells, but were unable 
to invade and proliferate.
Over the last 30 years, the repertoire of compounds 
containing transition metals with anti-tumor properties has 
expanded to include compounds containing Zn, Co, Ni, Sn, 
Ag, and Cd.43–49 Among these elements, cadmium has been 
ascribed elevated anti-tumor effects in comparison with 
other transition metals.43 In 2016, Sreekanth et al reported 
that cadmium oxide (CdO) NPs inhibited the proliferation 
of normal and tumor cell lines, whereby the tumor cells 
were more severely affected by CdO NPs.44 Our study 
shows that QDs-GSH have potent anti-tumor effects, as 
evidenced by the dramatic inhibition of cell proliferation 
and invasion following internalization of QDs-GSH. More-
over, the ability of such QD-GSH-labeled cells to form 
metastatic nodules in C57BL/6 mice was ablated within 
the time frame analyzed. Data from the literature favor the 
notion that these anti-metastatic effects are related to the 
presence of cadmium in the QDs-GSH core. Our results 
highlight the need to further investigate the anti-tumor 
effects of QDs-GSH, bearing in mind that selective tumor 
accumulation should permit using these QDs-GSH both as 
diagnostic agents and in anti-tumor therapy (theranostics).
Here, however, we focused on evaluating the utility of 
B16F10
QDs-GSH-10NAC
 in metastatic cells tracking at early stages 
post-injection, since they were able to migrate, but did not 
invade or proliferate.
In vivo distribution of B16F10QDs-gsh-10Nac 
cells
Previously, studies have shown that QDs can be followed by 
fluorescence microscopy in vitro and also to track interactions 
between different cell populations in vivo.12,50 For instance, 
this approach has permitted visualizing the clogging of 
blood vessels produced by B16-BL6 melanoma cells during 
metastasis.45 However, it was still not possible to track the 
accumulation or distribution of metastatic cells by in vivo 
fluorescence imaging.
To assess the potential utility of B16F10
QDs-GSH-10NAC
 cells 
in recording early steps of metastasis by in vivo fluorescence 
imaging, cells were injected (Figure 6A and B) into the 
tail vein of C57BL/6 mice and whole animal images were 
obtained using the IVIS. After injection of the cells into 
mice, the fluorescence signal was not detectable (Figure S4), 
likely because a number of biological molecules, including 
hemoglobin, absorb light between 400 and 600 nm, thereby 
interfering with the B16F10
QDs-GSH-10NAC
 signal. Thus, animals 
were sacrificed and after necropsy at the indicated time 
points, organs were placed in Fekete’s solution to eliminate 
blood traces and then fixed as described.46 Examples of lungs 
from C57BL/6 mice obtained after 6 hours inoculation with 
B16F10
QDs-GSH-10NAC
 cells are shown (Figure 6C). Fluores-
cence due to B16F10
QDs-GSH-10NAC
 presence in lungs was clearly 
distinguishable from the background fluorescence of controls 
(Figure 6D), suggesting the presence of B16F10
QDs-GSH-10NAC
 
in the lungs of C57BL/6 mice.
Using this approach, we determined the kinetics of 
B16F10 accumulation, particularly in the lungs of C57BL/6 
mice. To this end, 2×105 B16F10
QDs-GSH-10NAC
 cells were 
injected into the tail vein of mice and then the following 
organs were analyzed: 1) lungs (metastatic cell target); 
2) spleen, liver, and kidneys (principal QD storage organs 
post-intravenous injection) and; 3) heart and thymus (organs 
where no extensive accumulation of QDs has been previ-
ously described).47,48 Mice were sacrificed and organs were 
harvested at 5 minutes, 30 minutes, 2 hours, 6 hours, and 
24 hours post-injection, and the fluorescence was detected 
by direct imaging of the organs (Figure 6E–J). The greatest 
difference was observed in lungs harvested 6 hours after 
B16F10
QDs-GSH-10NAC
 injection (Figure 6E). Although a sig-
nificant increase in fluorescence was detectable as soon as 
5 minutes post-injection, the intensity increased until reach-
ing a maximum 6 hours post-injection. B16F10 cells prefer-
entially metastasize to the lungs of C57BL/6 mice, possibly 
due to their preference for laminin and/or fibronectin, two 
ECM proteins present surrounding small vessels of the lung, 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
20
0.
27
.7
2.
24
3 
on
 1
8-
De
c-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
6402
Díaz-garcía et al
???????????????????
?????????????
????????
????????
????????
??????
?
???????????????????
???????????????????
?????????????
?
???????????????????
???????????????????
????????????? ??????
?????
?????
?????
?
???
??? ?????????
??
?????
?? ????? ????
?? ????? ????? ?????
?
???
???
???
???
??
????????
??
?????
?? ????? ????
?? ????? ????? ?????
?
???
???
???
???
??
????????? ?
???
???????????
??
?????
?? ????? ????
?? ????? ????? ?????
?
???
???
???
???
??
????????
??
?????
?? ????? ????
?? ????? ????? ?????
?
???
???
???
???
??
?????????? ?
????????????
? ??
????????????????????
???????????????????????
??
?????
?? ????? ????
?? ????? ????? ?????
?
???
???
???
???
??
?????????
??
?????
?? ????? ????
?? ????? ????? ?????
?
???
???
???
???
??
?????????? ?
? ?????????????????????
?????? ? ? ? ??????? ????? ????? ??????
???????? ???????? ???????? ???????? ????????
? ????????????
?????????????
Figure 6 In vivo B16F10QDs-gsh-10Nac cell tracking.
Notes: B16F10QDs-gsh-10Nac cells were injected into the tail vein of C57BL/6 mice. rQDs-GSH signals were followed and quantified by imaging the signal in lungs. Organs 
were collected at 5 minutes, 30 minutes, 2 hours, 6 hours, and 24 hours post-injection. (A) a scheme summarizing the time course of early metastasis assays. (B) eppendorf 
tubes containing B16F10control and B16F10QDs-gsh-10Nac cells used for injection in c57Bl/6 mice. (C) Image showing lungs collected from c57Bl/6 mice 6 hours post-injection 
with either control or labeled cells (duplicate). (D) Fluorescence images of lungs collected from c57Bl/6 mice 6 hours post-injection with either control or labeled cells. 
(E–J) Quantification of rQDs-GSH-associated fluorescence in lungs, heart, kidneys, liver, spleen, and thymus of C57BL/6 mice at different time points after injection of 
B16F10control or B16F10QDs-gsh-10Nac cells. results were averaged from 12 independent experiments (n=12) for lung, heart, kidney, liver, spleen, and 4–10 independent 
experiments (n=4–10) for thymus. Data were analyzed using the nonparametric Mann–Whitney test. Statistically significant differences compared with the controls and 
different treatments are indicated. Note that the data shown were obtained in a double-blind study.
Abbreviations: B16F10QDs-gsh-10Nac, B16F10 cells labeled with rQDs-gsh in presence of 10 mM of Nac; gsh, glutathione; IVIs, in vivo imaging system; Nac, N-acetylcysteine; 
QDs, quantum dots; rQDs-gsh, red QDs-gsh.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
20
0.
27
.7
2.
24
3 
on
 1
8-
De
c-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
6403
Biomimetic quantum dot-labeled B16F10 murine melanoma cells
in the basal membrane and alveolar epithelium.28 These data 
correlate with previous studies, using QDs and fluorescence 
microscopy, indicating that 5 minutes after administration of 
B16-BL6 cells into the blood stream, these cells accumulated 
in small lung vessels.45
Several studies have shown that the majority of QDs 
present in the blood stream of mice rapidly accumulate in 
reticuloendothelial system organs (liver and spleen) and 
are excluded from heart and thymus.51–54 Nevertheless, no 
significant fluorescence increase in the spleen was detected 
when B16F10
QDs-GSH-10NAC
 cells were injected (Figure 6I), 
while fluorescence accumulation in the thymus was detected 
between 30 minutes and 2 hours post-injection (Figure 6J). 
These results suggest that rQDs-GSH remain confined within 
B16F10 cells and are in agreement with a previous report 
by Voura et al, showing that QDs were not released from 
QDs-DHLA-labeled B16F10 cells.12
The thymus is a lymphatic, endocrine, and immune organ 
where T cells mature and are released to the circulation.53 The 
cytotoxic T-cells, as well as natural killer T-cells, specifically 
participate in the early clearance of tumor cells from the blood 
stream.54,55 Given that the blood–thymus barrier prevents 
direct contact between the thymus and components of the 
blood stream,56,57 the observed pronounced accumulation of 
fluorescence in the thymus suggests that B16F10
QDs-GSH-10NAC
 
are being rapidly recognized by T cells.
Our results indicated that B16F10
QDs-GSH-10NAC
 cells were 
rapidly distributed (5 minutes) to the heart, liver, kidneys, and 
lungs of C57BL/6 mice and likely accumulated there by an 
embolic arrest process.24 However, despite the initial generic 
distribution, fluorescence intensity decreases in the other 
organs and a selective enrichment of B16F10
QDs-GSH-10NAC
 cells 
in lungs is observed within the first few hours post-injection. 
This suggests that B16F10
QDs-GSH-10NAC
 cells maintain the 
“homing” reported previously,24,25,45 and thus have the poten-
tial to be used as a tool for assessing early accumulation/
distribution of metastatic cells.
To confirm the presence of B16F10
QDs-GSH-10NAC
 cells in 
the lungs of C57BL/6 mice, lung sections obtained 6 hours 
post-injection of cells into the tail vein of C57BL/6 mice 
were analyzed by immunohistochemistry (Figure 7). Fluo-
rescence due to B16F10
QDs-GSH-10NAC
 presence was observed in 
histological slices from mice and was clearly distinguishable 
from the background fluorescence of controls (Figure 7A), 
confirming the presence of B16F10
QDs-GSH-10NAC
 cells in the 
lungs of C57BL/6 mice. During colonization of distant 
organs, the extravasation process is crucial.58 Given that 
B16F10 cells specifically target the lung in metastasis assays, 
it was important to determine whether B16F10
QDs-GSH-10NAC
 
cells were capable of transmigrating through the vascular 
endothelium and colonizing the lungs in vivo. With this in 
mind, B16F10
QDs-GSH-10NAC
 and Calcein AM-labeled B16F10 
(B16F10
Calcein
) cells were compared by histological analysis 
of lung sections 6 and 24 hours post-injection of cells into 
the tail vein of C57BL/6 mice. Specifically, we determined 
the fluorescence associated with B16F10
QDs-GSH-10NAC
 and 
B16F10
Calcein
 cells in the endothelial vasculature, alveolae, 
and bronchi (Figure S5A and B). B16F10
QDs-GSH-10NAC
 and 
B16F10
Calcein
 cells were mostly found in the perialveolar 
area, after 6 and 24 hours (Figure 7B and C). In addition, the 
number of cells present in those areas increased after 24 hours 
(Figure 7C), suggesting that the B16F10
QDs-GSH-10NAC
 cells 
transmigrated to the same extent as B16F10
Calcein
 cells. These 
results are consistent with previously published studies indi-
cating that QDs-DHLA-labeled B16F10 cells transmigrate 
in a manner similar to non-labeled B16F10 cells. However, 
the mechanism by which transmigration of QDs-labeled cells 
occurs had not been elucidated yet.
In this context, it is worth noting that transmigration can 
occur by at least three different processes or combinations of 
thereof: 1) mesenchymal cell invasion (protease dependent), 
2) collective cell invasion (protease dependent), and 3) amoe-
boid cell invasion (protease independent).58 Melanoma cells 
can invade using all three mechanisms and/or may switch 
from protease-dependent to amoeboid cell invasion.58,59 
Amoeboid invasion may explain why B16F10
QDs-GSH-10NAC
 
cells, that are non-invasive in a protease-dependent invasion 
assay (Figure 3C and E), display the same in vivo transmigra-
tion ability as B16F10
Calcein
 control cells (Figure 7B and C).
As shown in Figure S6, B16F10
QDs-GSH-10NAC
 cells 
(Figure S6A, Quadrant LR) and B16F10
Calcein
 cells 
(Figure S6B, Quadrant UL) exhibit similar MFI. Therefore, 
a similar intensity would be expected when these cells are 
present in organs. A decrease in fluorescence intensity 
was observed between 6 and 24 hours for rQDs-GSH and 
Calcein-labeled cells (Figure S6C). This result could explain 
the decrease in fluorescence observed in lungs after 24 hours 
(Figure 6E) and indicates that B16F10
QDs-GSH-10NAC
 cells are 
still present in the lungs at this time but with decreased 
fluorescence intensity. Also, these results indicate that 
6 hours post-injection represents the optimal time point for 
the tracking of organ-specific B16F10 cell accumulation and 
permits avoiding the possible loss of signal due to decreases 
in B16F10 cell fluorescence during the tracking process.
Of note, the fluorescence intensity due to rQDs-GSH was sig-
nificantly higher than that associated with Calcein after 24 hours 
(Figure S6C), suggesting that the rQDs-GSH labeling is more 
stable over time than fluorescence labeling using Calcein.
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Figure 7 Presence and distribution of B16F10QDs-gsh-10Nac and B16F10calcein cells in the lungs of c57Bl/6 mice.
Notes: B16F10QDs-gsh-10Nac, B16F10calcein, and control cells were injected into the tail vein of c57Bl/6 mice. Fluorescence signals due to either rQDs-gsh or calcein were 
determined in lungs at 6 and 24 hours post-injection. (A) confocal images of histological sections from lungs collected at 6 hours post-injection of B16F10QDs-gsh-10Nac or 
B16F10control cells. (B) confocal images of histological sections from lungs collected at 6 hours post-injection of B16F10QDs-gsh-10Nac or B16F10calcein cells. (C) confocal images 
of histological sections from lungs collected at 24 hours post-injection of B16F10QDs-gsh-10Nac or B16F10calcein cells. White arrows show fluorescence due to presence of 
B16F10QDs-gsh-10Nac or B16F10calcein cells. Note that the data shown were obtained in a double-blind study.
Abbreviations: B16F10QDs-gsh-10Nac, B16F10 cells labeled with rQDs-gsh in presence of 10 mM of Nac; gsh, glutathione; Nac, N-acetylcysteine; QDs, quantum dots; 
rQDs-gsh, red QDs-gsh.
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Finally, these results demonstrate that our methodology 
of QDs-GSH-labeling cells allows obtaining nearly 100% 
viable labeled cells with increased fluorescence signal. 
In addition, these cells can migrate, transmigrate, and 
maintain their “homing,” similar to the unlabeled B16F10 
cells. Thus, B16F10
QDs-GSH-10NAC
 cells can be used to track the 
early distribution/accumulation of B16F10 cells in C57BL/6 
organs by in vivo fluorescence imaging, without the need for 
fluorescence microscopy and, in doing so, monitor early steps 
involved in the colonization of distant organs.
Proof of concept
According to Sahai 2007, “the development of imaging 
studies can be important for preclinical evaluation of drugs 
that target steps in the metastatic process.”4 Our results 
showed that B16F10
QDs-GSH-10NAC
 cells can be used to track 
in vivo migration and the accumulation/distribution of meta-
static cells in C57BL/6 mice independently of the invasion 
process. We believe that this model has the potential to be 
used as a tool to determine more specifically how expression 
of different proteins in these cells and/or the application of 
drugs affect migration, accumulation, and/or distribution of 
B16F10
QDs-GSH-10NAC
 cells in C57BL/6 mice.
CAV-1 is an integral membrane protein, which has been 
shown to increase the migration, invasion, and metastasis of 
B16F10 cells.25,60 With this in mind, we performed a proof-
of-concept experiment, using B16F10 cells stably transfected 
with either the empty pLacIOP vector [B16F10(Mock) 
Figure 8 Proof-of-concept experiment to evaluate the effect of caV1 expression in labeled B16F10 cells following injection into c57Bl/6 mice.
Notes: B16F10(Mock) and B16F10(caV-1) cells were labeled with rQDs-gsh and used in this proof-of-concept experiment. (A) schematic summarizing the labeling assays 
of B16F10(Mock) or B16F10(caV-1) cells used in proof of concept. (B) Total viability of B16F10(Mock) and B16F10(caV-1) cells after labeling with rQDs-gsh. (C) Viability 
rQDs-gsh-labeled B16F10(Mock) and B16F10(caV-1) cells. (D) MFI of viable rQDs-gsh-labeled B16F10(Mock) and B16F10(caV-1) cells. (E) In vivo imaging of lungs 
collected from c57Bl/6 mice 6 hours post-injection with viable rQDs-gsh-labeled B16F10(Mock) and B16F10(caV-1) cells. results were averaged from three independent 
experiments (n=3). Data were analyzed using the nonparametric Mann–Whitney test. Treated cells that did not show statistically significant differences are indicated. Note 
that the data shown were obtained in a double-blind study.
Abbreviations: CAV-1, Caveolin-1; GSH, glutathione; MFI, mean fluorescence intensity; QDs, quantum dots; rQDs-GSH, red QDs-GSH.
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cells] or the vector containing the CAV1-encoding insert 
[B16F10(CAV-1) cells] that were then labeled with rQDs-
GSH as described in Figure 8A (B16F10
QDs-GSH-10NAC
). For 
the sake of simplicity, such labeled cells are referred to here 
as B16F10(Mock) and B16F10(CAV1) cells. Following 
labeling, we found that overall viability (Figure 8B), as well 
as the viability of labeled cells (Figure 8C), as determined 
by flow cytometry, were similar for B16F10(Mock) and 
B16F10(CAV1) cells. Moreover, the MFI was also similar 
(Figure 8D) for both types of cells as determined by flow 
cytometry. These results indicate that overexpression of 
CAV-1 in B16F10 cells neither altered the labeling with 
rQDs-GSH nor the viability of labeled B16F10 cells. B16F10 
cells do not express PTRF/Cavin-1,28,61 and also lack the 
presence of caveolae-like structures at the cell surface. More-
over, immunofluorescence studies have shown that the large 
majority of the CAV1 protein in B16F10(CAV1) cells is intra-
cellular, predominantly in a perinuclear location,28 consistent 
with the notion that the presence of CAV1 in B16F10(CAV1) 
cells does not modulate QDs-GSH internalization.
Subsequently, 2×105 viable and rQDs-GSH-labeled 
B16F10(Mock) or B16F10(CAV-1) cells were injected into 
the tail vein of C57BL/6 mice, and 6 hours post-injection 
lungs from those recipient mice were collected for ex vivo 
fluorescence tracking using IVIS. As shown in Figure 8E, 
fluorescence intensity observed in lungs was greater for mice 
injected with B16F10(CAV-1) cells than those that received 
B16F10(Mock) cells. This result suggests that enhanced 
expression of CAV-1 in B16F10 melanoma cells promotes 
experimental lung metastasis described previously by our 
group by enhancing the accumulation of B16F10 cells in 
the lungs of recipient mice. In doing so, these experiments 
validate the potential of using rQDs-GSH-labeled cells to 
monitor early steps in metastasis.
Conclusion
In the present study, we describe for the first time the effects 
of biomimetic QDs-GSH incorporation on the viability 
and metastatic behavior of B16F10 cells. Also, we define 
a novel methodology that permits ameliorating detrimental 
consequences of QDs-GSH uptake. QDs-GSH’ incorpora-
tion augments ROS and cell migration in B16F10 cells; 
however, these effects can be corrected by NAC treatment. 
In addition, NAC treatment allows increasing significantly 
the viability and fluorescence intensity of rQDs-GSH-labeled 
cells. However, proliferation and invasiveness of B16F10 
cells, as well as the formation of metastatic lung nodules, 
were all attenuated by QDs-GSH internalization, probably 
as a consequence of cadmium present in the QDs-GSH core. 
Moreover, we show that QDs-GSH-labeled B16F10 cells can 
be used to track the in vivo migration and early distribution/
accumulation of these cells in C57BL/6 organs. Our study 
reveals that these cells preferentially accumulated in lungs 
of C57BL/6 mice as early as 5 minutes post-injection. Thus, 
although QDs-GSH internalization blocks the ability of 
B16F10 cells to form nodules in the lung, QDs-GSH-labeled 
B16F10 cells can be successfully tracked during the early 
steps involved in the colonization of distant organs.
Finally, our study provides a cell-labeling methodology 
that should be useful for characterizing the early steps of 
tissue-specific accumulation and distribution of B16F10 cells 
in C57BL/6 mice, as well as help to evaluate the effects of 
drugs and/or different biological factors (cytokines, signaling 
proteins, etc.) on these processes and, in doing so, improve 
our understanding of these events. With this in mind, we 
propose that QDs-GSH can be expected to have considerable 
potential for future use in cancer theranostics.
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Figure S1 TeM image of rQDs-gsh.
Notes: rQDs-gsh were observed by TeM microscopy and the core size was determined using ImageJ software. (A) TeM image of rQDs-gsh. (B) A threefold amplification 
of square shown in image a. (C) Quantification of electron-dense granule size (core of rQDs-GSH).
Abbreviations: gsh, glutathione; QDs, quantum dots; rQDs-gsh, red QDs-gsh; TeM, transmission electron microscopy.
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Figure S2 Intracellular reduced thiol levels in MKN45 and B16F10 cells.
Notes: Intracellular rsh levels in MKN45 and B16F10 cells were measured by ellman’s assay. results were averaged from three independent experiments (n=3). Data were 
analyzed using the nonparametric Mann–Whitney test. Statistically significant differences are indicated.
Abbreviation: rsh, reduced thiols.
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Figure S3 effects of QDs-gsh incorporation on B16F10 cell proliferation and evaluation of QDs-gsh signal after 24 hours.
Notes: 1×105 B16F10 cells (white bars) and B16F10 cells labeled with rQDs-gsh (gray bars) were cultured in rPMI supplemented with 10% FBs for 24 hours, and cell 
viability, percentage of viable labeled cells, MFI, and the total cell number (quantification of proliferation) were determined after cell labeling. (A) cell viability at 0 or 24 hours 
post-labeling. (B) Percentage of viable B16F10 cells at 0 or 24 hours post-labeling. (C) MFI of viable B16F10 cells at 0 or 24 hours post-labeling. (D) Total number of B16F10 
cells at 0 or 24 hours post-labeling. results were averaged from three independent experiments (n=3). Data were analyzed using the nonparametric Mann–Whitney test. The 
n.s. significant differences compared with the controls and different treatments are indicated.
Abbreviations: GSH, glutathione; MFI, mean fluorescence intensity; n.s., non-statistically; QDs, quantum dots; rQDs-GSH, red QDs-GSH.
? ? ? ??????
??????
??????
??????
Figure S4 In vivo imaging of c57Bl/6 mice treated with B16F10QDs-gsh-10Nac and B16F10 control cells.
Notes: B16F10QDs-gsh-10Nac (1 and 3) and B16F10 control cells (2) were injected into c57Bl/6 mice. Fluorescence signals for rQDs-gsh were followed in mice for 6 hours. 
Imaging shows no differences in fluorescence signals between the mice.
Abbreviations: B16F10QDs-gsh-10Nac, B16F10 cells labeled with rQDs-GSH in presence of 10 mM of NAC; GSH, glutathione; MFI, mean fluorescence intensity; NAC, 
N-acetylcysteine; QDs, quantum dots; rQDs-gsh, red QDs-gsh.
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Figure S5 Controls of histological assays: fluorescence signals due to rQDs-GSH or Calcein were followed in lungs 6 hours post-injection of unlabeled B16F10 cells.
Notes: (A) light microcopy images of histological sections from lungs collected 6 hours post-injection of unlabeled B16F10 cells and stained with hematoxylin and eosin. 
Images show various tissue areas where B16F10 cells were identified. (B) confocal images of histological sections from lungs collected 6 hours post-injection of unlabeled 
B16F10 cells. Phalloidin green, red, and DaPI were used as a contrast media. No signals related to rQDs-gsh or calcein were observed.
Abbreviations: gsh, glutathione; QDs, quantum dots; rQDs-gsh, red QDs-gsh.
Figure S6 (Continued)
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Figure S6 Fluorescence intensity of B16F10QDs-gsh-10Nac and B16F10calcein cells at 6 and 24 hours post-injection: dot plot obtained by flow cytometry and the respective 
quantification of mean fluorescence intensity in each quadrant.
Notes: (A) B16F10QDs-gsh-10Nac cells. (B) B16F10calcein cells. (C) Fluorescence due to the presence of B16F10QDs-gsh-10Nac and B16F10calcein cells in histological slices was 
measured with ImageJ 1.47 v software (National Institutes of Health, USA). Results were averaged from five independent experiments (n=5). Data were analyzed using the 
nonparametric Mann–Whitney test. Statistically significant differences are indicated.
Abbreviations: B16F10QDs-gsh-10Nac, B16F10 cells labeled with rQDs-gsh in presence of 10 mM of Nac; gsh, glutathione; Nac, N-acetylcysteine; QDs, quantum dots; 
rQDs-gsh, red QDs-gsh.
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